MedPath

TO COMPARE THE CLINICAL OUTCOME OF FAST TRACK PROTOCOLS AND CONVENTIONAL PROTOCOLS ON PATIENTS UNDERGOING EMERGENCY LAPAROTOMIES- A RANDOMIZED STUDY

Phase 1/2
Not yet recruiting
Conditions
Perforation of intestine (nontraumatic),
Registration Number
CTRI/2019/09/021282
Lead Sponsor
Jyoti Sharma
Brief Summary

This prospective double blinded study is being undertaken to compare the clinical outcomes of application of ERAS protocols and conventional care protocols on patients undergoing Emergency Laparotomies for Acute Intestinal perforations and Acute Intestinal Obstructions. Our aim is toinvestigate the feasibility and beneficial effects of Enhanced recovery aftersurgery in the setting of emergency laparotomy. The primary outcomes are tocompare the surgical outcome in terms of post operativecomplications,mortality, length of stay and re admission rate in patients withacute abdomen undergoing emergency laparotomy with ERAS protocols and those with conventional post operativecare. The secondary objectives are toevaluate the applicability,safety and effectiveness of ERAS in emergencysurgeries and tostandardise and optimise peri operative care in order to reduce surgicaltrauma,peri operative physiological stress and organ dysfunction. The patients will be randomly divided intotwo groups using a computer generated allocation software(Random AllocationSoftware)and allocation concealment will be done by a sealed envelope toprevent prior knowledge of treatment assignment. The numbers will be assignedin strict chronological sequence and study participants will be entered in thesequence. Each study patient will be allocated a unique randomization number onsuccessful completion of screening, to be assigned to receive either one of thegroups. The patients will be assessed postoperatively for complications, mortality,length of stay and readmission rate.The patients will be followed up till 30 days post operatively. The primary endpoints will be thelength of hospital stay and morbidity and mortality during the first 30 daysafter surgery. Morbidities will include superficialand organ/space-type SSIs, postoperative ileus, pulmonary complicationsincluding atelectasis and  pleuraleffusion and postoperative bleeding. The secondary endpoints will be the time elapsed until theresumption of oral feeding, the need for nasogastric tube reinsertion, the needfor extra analgesics, the readmission rate, and the reoperation rate.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria
  • 1.Age >18 years with pre operatively diagnosed perforation peritonitis and acute intestinal obstruction planned for emergency laparotomies.
  • 2.ASA grade Ie to IIIe 3.Hemodynamically stable 4.Patients giving Informed consent for the study.
Exclusion Criteria
  • 1.Pregnant patients.
  • 2.Patients on chronic steroids.
  • 3.Spontaneously sealed-off perforated ulcers that were diagnosed either preoperatively or during surgery and that did not require surgical repair.
  • 4.Malignant ulcers confirmed by histopathological examination if biopsied for a high index of suspicion for malignancy.
  • 5.Laparoscopic surgeries.
  • 6.Acute abdominal trauma surgeries.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
2.Morbidity and mortality during the first 30 days after surgery1.The length of hospital stay. | 2.Morbidity and mortality during the first 30 days after surgery
1.The length of hospital stay.1.The length of hospital stay. | 2.Morbidity and mortality during the first 30 days after surgery
Secondary Outcome Measures
NameTimeMethod
The time elapsed until the resumption of oral feeding, the need for nasogastric tube reinsertion, the need for extra analgesics, the readmission rate, and the reoperation rate.30 days

Trial Locations

Locations (1)

AIIMS Rishikesh

🇮🇳

Dehradun, UTTARANCHAL, India

AIIMS Rishikesh
🇮🇳Dehradun, UTTARANCHAL, India
Jyoti Sharma
Principal investigator
8860314670
js130193@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.